Induced pluripotent stem cells and genome editing technology as therapeutic strategies for Duchenne muscular dystrophy

Irwan Saputra Batubara(1*)

(1) Division of Surgical and Interventional Science, University Colllege London
(*) Corresponding Author


Duchenne muscular dystrophy (DMD) is a rare genetic, progressive
and devastating skeletal and cardiac muscle disorder due to mutation
of the dystrophin gene that affects 1 in 3500 young males. Currently,
there is no curative management for this pathology. The development of
inducedpluripotent stem cells (iPSCs) offers a promising cell-based strategy
for the treatment of muscular dystrophy. Several techniques have been
established to generate functional myogenic progenitor cells derived from
iPSCs. In addition, technologies in genetic modification using ZFN, TALENs, or
CRISPR/Cas9 demonstrate potent methods to restore dystrophin expression.
However, current evidence shows that either iPSCs or gene editing carry
a risk of oncogenesis caused by the integration of exogenous DNA into the
recipient gene. Thus, the safety issue is a major challenge for translating
this method into human clinical applications. This review briefly discussed
recent developments and progressions of iPSCs as well as genome engineering
technologies relevant to regenerative medicine, especially for the treatment
of DMD.


induced pluripotent; stem cells; Duchenne muscular dystrophy; gene editing; cell-based therapy

Full Text:



Article Metrics

Abstract views : 1341 | views : 2511

Copyright (c) 2021 Irwan Saputra Batubara

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

View My Stats


Creative Commons License
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) by  Universitas Gadjah Mada is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.